Functional expression of CD80 and CD86 allows immunogenicity of malignant B cells from non-Hodgkin's lymphomas

Experimental Hematology

Volumn 27, Issue 3, 1999, Pages 479-488

  Chaperot, Laurence ^a,b   Plumas, Joël ^a,b   Jacob, Marie Christine ^a,b   Bost, Frédérique ^c   Molens, Jean Paul ^a,b   Sotto, Jean Jacques ^b,c   Bensa, Jean Claude ^a,b  

^a ETS de l'Isere et de la Savoie   (France)

^b Research Group on Lymphomas UA2021   (France)

^c HÔPITAL MICHALLON   (France)

Author keywords

Antigen presentation; CD80; CD86; Mixed lymphocyte reaction; Non Hodgkin's lymphoma

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN;

ADULT; AGED; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CLINICAL ARTICLE; FEMALE; HUMAN; IMMUNOGENICITY; IMMUNOSTIMULATION; LYMPHOCYTE PROLIFERATION; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL;

ADULT; AGED; ANIMALS; ANTIGEN PRESENTATION; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD; ANTIGENS, CD40; ANTIGENS, CD80; ANTIGENS, CD86; B-LYMPHOCYTES; CD40 LIGAND; FEMALE; HUMANS; INTERLEUKIN-4; L CELLS (CELL LINE); LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; LYMPHOMA, B-CELL; LYMPHOMA, HIGH-GRADE; LYMPHOMA, LOW-GRADE; MALE; MEMBRANE GLYCOPROTEINS; MICE; MIDDLE AGED; TRANSFECTION;

EID: 0032982051     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(98)00059-9     Document Type: Article

References (39)

1. Horning S.J. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol. 20:1993;75.
2. Hsu F.J., Benike C., Fagnoni F., Liles T.M., Czerwinski D., Taidi B., Engleman E.G., Levy R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med. 2:1996;52.
3. Springer T.A. Adhesion receptors of the immune system. Nature. 346:1990;425.
4. June C.H., Bluestone J.A., Nadler L.M., Thompson C.B. The B7 and CD28 receptor families. Immunol Today. 15:1994;321.
5. Noel P.J., Boise L.H., Green J.M., Thompson C.B. CD28 costimulation prevents cell death during primary T cell activation. J Immunol. 157:1996;636.
6. Radvanyi L.G., Shi Y.F., Vaziri H., Sharma A., Dhala R., Mills G.B., Miller R.G. CD28 costimulation inhibits TCR-induced apoptosis during a primary T cell response. J Immunol. 156:1996;1788.
7. Mamula M., Janeway C. Do B cells drive the diversification of immune responses. Immunol Today. 14:1993;151.
8. Ho W.Y., Cooke M.P., Goodnow C.C., Davis M.M. Resting and anergic B cells are defective in CD28-dependent costimulation of naive CD4(+) T cells. J Exp Med. 179:1994;1539.
9. Croft M., Bradley L.M., Swain S.L. Naive versus memory CD4 T cell response to antigen - memory cells are less dependent on accessory cell costimulation and can respond to many antigen-presenting cell types including resting B cells. J Immunol. 152:1994;2675.
10. Krieger J.I., Grammer S.F., Grey H.M., Chesnut R.W. Antigen presentation by splenic B cells. resting B cells are ineffective, whereas activated B cells are effective accessory cells for T cell responses J Immunol. 135:1985;2937.
11. Freeman G.J., Freedman A.S., Segil J.M., Lee G., Whitman J.F., Nadler L.M. B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J Immunol. 143:1989;2714.
12. Azuma M., Ito D., Yagita H., Okumura K., Phillips J.H., Lanier L.L., Somoza C. B70 antigen is a 2nd ligand for CTLA-4 and CD28. Nature. 366:1993;76.
13. Constant S., Schweitzer N., West J., Ranney P., Bottomly K. B lymphocytes can be competent antigen-presenting cells for priming CD4(+) T cells to protein antigens in vivo. J Immunol. 155:1995;3734.
14. Medeiros L.J., Gelb A.B., Wolfson K., Doggett R., Mcgregor B., Cox R.S., Horning S.J., Warnke R.A. Major histocompatibility complex Class-I and Class-II antigen expression in diffuse large cell and large cell immunoblastic lymphomas - absence of a correlation between antigen expression and clinical outcome. Am J Pathol. 143:1993;1086.
15. Freedman A.S. Expression and function of adhesion receptors on normal B-cells and B-cell non-Hodgkin's lymphomas. Semin Hematol. 30:1993;318.
16. Johnson P.W.M., Watt S.M., Betts D.R., Davies D., Jordan S., Norton A.J., Lister T.A. Isolated follicular lymphoma cells are resistant to apoptosis and can be grown in vitro in the CD40/stromal cell system. Blood. 82:1993;1848.
17. Munro J.M., Freedman A.S., Aster J.C., Gribben J.G., Lee N.C., Rhynhart K.K., Banchereau J., Nadler L.M. In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease. Blood. 83:1994;793.
18. Plumas J., Chaperot L., Jacob M.C., Giroux C., Mollens J.P., Sotto J.J., Bensa J.C. Malignant B lymphocytes induce allogeneic proliferative and cytotoxic T cell responses in primary mixed lymphocyte cultures. Eur J Immunol. 25:1995;3332.
19. Dorfman D.M., Schultze J.L., Shahsafaei A., Michalak S., Gribben J.G., Freeman G.J., Pinkus G.S., Nadler L.M. In vivo expression of B7.1 and B7.2 by follicular lymphoma cells can prevent induction of T-cell anergy but is insufficient to induce significant T-cell proliferation. Blood. 90:1997;4297.
20. Harris N.L., Jaffe E.S., Stein H., Banks P.M., Chan J.K.C., Cleary M.L., Delsol G., Dewolfpeeters C., Falini B., Gatter K.C., Grogan T.M., Isaacson P.G.et al. A revised European-American classification of lymphoid neoplasms. a proposal from the International Lymphoma Study Group Blood. 84:1994;1361.
21. Pellegrino M., Ferrone S., Theofilopoulos A. Isolation of human T and B cells by rosette formation with 2-aminoethylisothiouronium bromide (AET)-treated sheep red blood cells and with monkey red blood cells. J Immunol Methods. 11:1976;273.
22. Garrone P., Neidhardt E.M., Garcia E., Galibert L., van Kooten C., Banchereau J. Fas ligation induces apoptosis of CD40-activated human B lymphocytes. J Exp Med. 182:1995;1265.
23. Banchereau J., De Paoli P., Valle A., Garcia E., Rousset F. Long term human B cell lines dependent on interleukin 4 and antibody to CD40. Science. 251:1991;70.
24. Vyth-Dreese F.A., Dellemijn T.A.M., Majoor D., de Jong D. Localization in situ of the co-stimulatory molecules B7.1, B7.2, CD40 and their ligands in normal lymphoid tissue. Eur J Immunol. 25:1995;3023.
25. Dazzi F., Dandrea E., Biasi G., Desilvestro G., Gaidano G., Schena M., Tison T., Vianello F., Girolami A., Caligariscappio F. Failure of B cells of chronic lymphocytic leukemia in presenting soluble and alloantigens. Clin Immunol Immunopathol. 75:1995;26.
26. Cardoso A.A., Schultze J.L., Boussiotis V.A., Freeman G.J., Seamon G.J., Laszlo S., Billet A., Sallan S.E., Gribben G.J., Nadler L.M. Pre-B acute lymphoblastic leukemia cells may induce T-cell anergy to alloantigen. Blood. 88:1996;41.
27. Ranheim E.A., Kipps T.J. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med. 177:1993;925.
28. Caux C., Burdin N., Galibert L., Hermann P., Renard N., Servetdelprat C., Banchereau J. Functional CD40 on B lymphocytes and dendritic cells. Res Immunol. 145:1994;235.
29. Yellin M.J., Sinning J., Covey L.R., Sherman W., Lee J.J., Glickman-Nir E., Sippel K.C., Rogers J., Cleary A.M., Parker M., Chess L., Lederman S. T lymphocyte T cell-B cell-activating molecule/CD40-L molecules induce normal B cells or chronic lymphocytic leukemia B cells to express CD80 (B7/BB-1) and enhance their costimulatory activity. J Immunol. 153:1994;666.
30. Stack R.M., Lenschow D.J., Gray G.S., Bluestone J.A., Fitch F.W. IL-4 treatment of small splenic B cells induces costimulatory molecules B7-1 and B7-2. J Immunol. 152:1994;5723.
31. Schultze J.L., Cardoso A.A., Freeman G.J., Seamon M.J., Daley J., Pinkus G.S., Gribben J.G., Nadler L.M. Follicular lymphomas can be induced to present alloantigen efficiently. a conceptual model to improve their tumor immunogenicity Proc Natl Acad Sci USA. 92:1995;8200.
32. Bohmig G.A., Kovarik J., Holter W., Pohanka E., Zlabinger G.J. Specific down-regulation of proliferative T cell alloresponsiveness by interference with CD2/LFA-3 and LFA-1/ICAM-1 in vitro. J Immunol. 152:1994;3720.
33. Nelson E.L., Li X., Hsu F.J., Kwak L.W., Levy R., Clayberger C., Krensky A.M. Tumor specific cytotoxic T-lymphocyte response after idiotype vaccination for B-cell non-Hodgkin's lymphoma. Blood. 88:1996;580.
34. Jacob M.C., Piccini M.P., Bonnefoix T., Sotto M.F., Couderc P., Bensa J.C., Sotto J.J. T lymphocytes from invaded lymph nodes in patients with B-cell-derived non-Hodgkin's lymphoma. reactivity toward the malignant clone Blood. 75:1990;1154.
35. Shi I., Bonnefoix T., Heuzelevacon F., Jacob M.C., Leroux D., Gressin R., Sotto M.F., Chaffanjon P., Bensa J.C., Sotto J.J. Autotumour reactive T-cell clones among tumour-infiltrating T lymphocytes in B-cell non-hodgkin's lymphomas. Br J Haematol. 90:1995;837.
36. Kudoh S., Wang Q., Hidalgo O.F., Rayman P., Tubbs R.R., Edinger M.G., Kolenko V., Panuto J., Bukowski R., Finke J.H. Responses to T cell receptor CD3 and interleukin-2 receptor stimulation are altered in T cells from B cell non hodgkin's lymphomas. Cancer Immunol Immunother. 41:1995;175.
37. Wang Q., Stanley J., Kudoh S., Myles J., Kolenko V., Yi T.L., Tubbs R., Bukowski R., Finke J. T cells infiltrating non-Hodgkin's B cell lymphomas show altered tyrosine phosphorylation pattern even though T cell receptor/CD3-associated kinases are present. J Immunol. 155:1995;1382.
38. Plumas J., Jacob M.C., Chaperot L., Molens J.P., Sotto J.J., Bensa J.C. Tumor B cells from non-Hodgkin's lymphoma are resistant to CD95 (Fas/Apo-1)-mediated apoptosis. Blood. 91:1998;2875.
39. Chaperot L., Jacob M.C., Molens J.P., Dascalescu C., Sotto J.J., Bensa J.C., Plumas J. Development of antitumor cytotoxic T lymphocytes in B-cell Non-Hodgkin's lymphomas. Blood. 90(suppl. 1):1997;513a.